Clinical trial
Study of Recombinant Adenovirus (AdVince) in Patients With Neuroendocrine Tumors; Safety and Efficacy
NCT02749331 is registered in ClinicalTrials.gov with Uppsala University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study of Recombinant Adenovirus (AdVince) in Patients With Neuroendocrine Tumors; Safety and Efficacy
- Lead sponsor
- Uppsala University
- Phase
- Phase 1/2
- Overall status
- Active, not recruiting
- Start date
- March 31, 2016
- Completion date
- December 31, 2025
- Enrollment
- 35 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.